Skip to main content
    M

    Mink Therapeutics Inc (INKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.95
    -0.40 (-3.86%)

    Market Cap: $52.20M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(14/21)
    Avg Surprise
    -31.30%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.35 - $-0.35
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.91+61.5%
    60d ago$-0.63+44.4%
    30d ago$-0.63+44.4%
    7d ago$-0.63+44.4%
    Current$-0.35
    Revenue Consensus
    $2M
    Range$2M - $2M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.21
    Range$-0.21 - $-0.21
    1 analysts
    Revenue Consensus
    $2M
    Range$2M - $2M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.21---
    Sep 26EST
    		-$-0.35---
    Jun 26
    Reported Aug 13
    		$-0.62$-0.60-3.33%Miss+41.5%
    Mar 26
    Reported May 15
    		$-0.57$-0.77+25.97%Beat+18.6%
    Dec 25
    Reported Mar 17
    		$-0.56$-0.68+17.65%Beat+9.7%
    Sep 25
    Reported Nov 14
    		$-0.65$-0.85+23.53%Beat-30.0%
    Jun 25
    Reported Aug 14
    		$-1.06$-0.55-92.73%Miss-51.4%
    Mar 25
    Reported May 15
    		$-0.70$-0.61-14.75%Miss+36.4%
    Dec 24
    Reported Mar 18
    		$-0.62$-0.08-675.00%Miss-287.5%
    Sep 24
    Reported Nov 14
    		$-0.50$-0.80+37.50%Beat+66.7%
    Jun 24
    Reported Aug 13
    		$-0.70$-0.97+27.84%Beat+61.1%
    Mar 24
    Reported May 14
    		$-1.10$-1.53+28.10%Beat+35.3%
    Dec 23
    Reported Mar 21
    		$-0.16$-0.15-6.67%Miss+30.4%
    Sep 23
    Reported Nov 9
    		$-1.50$-1.82+17.58%Beat+21.1%
    Jun 23
    Reported Aug 10
    		$-1.80$-1.97+8.63%Beat+0.0%
    Mar 23
    Reported May 11
    		$-1.70$-2.37+28.27%Beat+26.1%
    Dec 22
    Reported Mar 21
    		$-0.23$-0.21-9.52%Miss-27.8%
    Sep 22
    Reported Nov 3
    		$-1.90$-2.33+18.45%Beat+67.8%
    Jun 22
    Reported Aug 9
    		$-1.80$-2.40+25.00%Beat-757.1%
    Mar 22
    Reported May 10
    		$-2.30$-2.30+0.00%Beat-992.1%
    Dec 21
    Reported Mar 18
    		$-0.18N/A+56.10%Beat+14.5%
    Sep 21
    Reported Oct 15
    		$-5.90$-2.00-195.00%Miss-3658.0%
    Jun 21
    Reported Sep 1
    		$-0.21$-0.28+25.00%Beat-33.8%
    Mar 21
    Reported Jun 30
    		$-0.21$0.00N/AMiss-17.1%
    Dec 20
    Reported Mar 30
    		$-0.21$0.00N/AMiss-17.1%
    Sep 20
    Reported Dec 31
    		$-0.16$0.00N/AMiss-
    Jun 20
    Reported Sep 30
    		$-0.16$0.00N/AMiss-
    Mar 20
    Reported Jun 29
    		$-0.18$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-0.18$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.15EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-1239.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage36.49x
    Current Ratio1.23xQuick Ratio1.23x
    Trading Statistics
    Beta0.47Avg Volume18.09K
    52-Week High$16.9352-Week Low$8.48

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.05
    SMA 20$11.67
    SMA 50$11.56
    SMA 200$11.38
    EMA 10$10.86
    EMA 20$11.28
    EMA 50$11.47
    EMA 200$11.49

    MACD

    Line: -0.39Signal: -0.13Hist: -0.26

    ADX

    ADX: 30.2+DI: 11.8-DI: 25.6

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down100.0
    PSAR$11.83

    Bollinger Bands

    Upper Band$13.42
    Lower Band$9.92
    %B Position3004%(Upper)
    Band Width0.01

    RSI (14-Day)

    Oversold
    29.1

    Momentum Oscillators

    Stoch %K4.5
    Stoch %D5.0
    Williams %R-99.5
    ROC (10d)-21.8%
    Momentum-2.78
    CCI (20d)-153.2
    MFI (14d)36.3

    Volatility Measures

    ATR (14d)$0.58(5.8%)
    StdDev (20d)0.88
    Hist Vol35.3%(Moderate)

    Volume Flow

    VWAP$10.08
    OBV55.5M
    AD Line9.9M
    CMF (20d)-0.147

    Volume Metrics

    Avg Vol (20d)19.5K
    Vol Ratio0.5x
    VWMA (20d)$11.95

    Pivot Points

    R3$10.70
    R2$10.52
    R1$10.44
    Pivot Point$10.26
    S1$10.18
    S2$10.00
    S3$9.92

    Advanced Oscillators

    TSI-21.04
    Ultimate Osc27.4
    KST-40.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$3.77B$0$0$0$-11,708,192,000$0
    Cost of Revenue$0$0$38,563$0$0$0$53,869$0$0$0$53,572$0
    Gross Profit$0$0$-38,563$0$0$0$-53,869$0$0$0$-53,572$0
    Operating Expenses$3.22M$2.88M$2.71M$3.18M$4.05M$2.70M$2.50M$1.88M$3.07M$3.83M$5.50M$5.22M
    R&D$1.89M$1.20M$1.51M$1.14M$1.84M$1.26M$1.41M$540,638$1.84M$2.55M$3.31M$3.43M
    SG&A$1.33M$1.68M$1.76M$1.85M$1.85M$1.27M$808,906$1.16M$1.06M$1.28M$2.19M$1.80M
    Operating Income$-3,216,894$-2,881,787$-2,705,459$-3,183,594$-4,052,396$-2,700,687$-2,502,678$-1,884,612$-3,071,081$-3,829,914$-5,500,104$-5,223,561
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-72,884$-80,834$-111,230$-55,151$-348$-13,517$-39,574$-78,015$-38,360$-16,619$-41,525$-107,287
    Income Before Tax$-3,128,201$-2,742,368$-2,602,103$-2,887,709$-4,237,751$-2,766,697$-2,463,104$-1,806,597$-2,701,806$-3,813,295$-5,458,597$-5,116,266
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,128,201$-2,742,368$-2,602,103$-2,887,709$-4,237,751$-2,766,697$-2,463,104$-1,806,597$-2,701,806$-3,813,295$-5,458,597$-5,116,266
    EBITDA$-3,165,021$-2,787,136$-2,674,770$-2,899,206$-4,189,336$-2,729,449$-2,448,809$-1,821,975$-2,695,066$-3,776,083$-5,446,550$-5,170,100
    EBIT$-3,201,085$-2,823,202$-2,713,333$-2,942,860$-4,238,099$-2,780,214$-2,502,678$-1,884,612$-2,740,166$-3,829,914$-5,500,122$-5,223,553
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INKT

    News

    Mink Therapeutics CEO Buell sells $73,265 in stock for tax obligations

    Jennifer Buell, CEO of MiNK Therapeutics, sold 6,938 shares of company stock for $73,265 on October 12, 2026, to cover tax obligations from vested restricted stock units. This sale followed her acquisition of 23,191...

    Investing.com•10/15/26•Neutral

    Form 4 Mink Therapeutics Inc: Jennifer Buell (Director, CEO) For: 11 October

    This article reports a Form 4 filing for Mink Therapeutics Inc, indicating that Jennifer Buell, who holds roles as Director and CEO...

    Investing.com India•10/15/26•Neutral

    Mink Therapeutics CEO Buell sells $73,265 in stock for tax obligations

    Jennifer Buell, CEO of MiNK Therapeutics, sold 6,938 shares worth $73,265 to cover tax obligations related to restricted stock unit vesting. This sale occurred shortly after she acquired 23,191 shares through RSU...

    Investing.com India•10/15/26•Neutral

    Form 4 Mink Therapeutics Inc: Jennifer Buell (Director, CEO) For: 11 October

    This article reports a Form 4 filing for Mink Therapeutics Inc., detailing a transaction made by Jennifer Buell, who serves as both a Director and CEO of the company. The filing pertains to activity on October 11...

    Investing.com Nigeria•10/15/26•Neutral

    MiNK Therapeutics (INKT) CEO sells 6,938 shares solely to cover taxes owed upon vesting.

    MiNK Therapeutics CEO Jennifer Buell sold 6,938 common shares at a weighted average price of $10.56 per share on October 12...

    Stock Titan•10/14/26•Neutral

    INKT Valuation and Fair Value

    P/E
    -4.1x
    P/B
    -3.6x
    See GNG's fair value

    INKT Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -1239.0%

    INKT Competitors

    CompanyTicker
    Inspira Technologies Oxy BHN LtdIINN
    Alterity Therapeutics LtdATHE
    Kalaris Therapeutics, Inc.KLRS
    Myomo IncMYO
    DarioHealth CorpDRIO
    iBio, Inc. Common StockIBIO
    Kezar Life Sciences IncKZR
    Tela Bio IncTELA

    Sector: Healthcare

    INKT Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -85.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.35
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About INKT

    Does INKT pay dividends?

    Mink Therapeutics Inc (INKT) does not currently pay a regular dividend.

    What is INKT's market cap?

    Mink Therapeutics Inc (INKT) has a market capitalization of $52.20M with a current stock price of $9.95.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In